A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 623 participants.

Also called NCT05680129

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 623 participants (enrolled count) (from the registry)
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd. (from the registry)
Registry
  • NCT NCT05680129
Other papers using this trial's data
  • Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial The lancet. Diabetes & endocrinology, 2025-10 DOI, PubMed 40854315

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05680129. Randomized; no masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2024-07-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Condition
T2DM
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ecnoglutide high dosage
Intervention (Drug)
Ecnoglutide low dosage
Intervention (Drug)
Dulaglutide
Intervention (Drug)
Metformin
Lead sponsor
Hangzhou Sciwind Biosciences Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05680129
Content hash
6d58cab0c6f5f52c6580f6063f2912b8ec3486a5b0a34318ea493e911788a90a